MOLN Stock Overview
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Molecular Partners AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF3.26 |
| 52 Week High | CHF6.30 |
| 52 Week Low | CHF3.04 |
| Beta | 0.78 |
| 1 Month Change | -11.89% |
| 3 Month Change | -18.50% |
| 1 Year Change | -43.50% |
| 3 Year Change | -85.45% |
| 5 Year Change | -81.56% |
| Change since IPO | -85.45% |
Recent News & Updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Molecular Partners AG's (VTX:MOLN) CEO Compensation
Apr 11
Is Molecular Partners (VTX:MOLN) In A Good Position To Invest In Growth?
Jan 09Here's Why We're Watching Molecular Partners' (VTX:MOLN) Cash Burn Situation
Sep 08Need To Know: The Consensus Just Cut Its Molecular Partners AG (VTX:MOLN) Estimates For 2023
Jun 23What You Need To Know About The Molecular Partners AG (VTX:MOLN) Analyst Downgrade Today
Aug 31Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
May 09Upgrade: Analysts Just Made A Substantial Increase To Their Molecular Partners AG (VTX:MOLN) Forecasts
Dec 26We're Hopeful That Molecular Partners (VTX:MOLN) Will Use Its Cash Wisely
Jun 24Molecular Partners AG (VTX:MOLN) Could Be Less Than A Year Away From Profitability
Mar 09Analysts Just Made A Major Revision To Their Molecular Partners AG (VTX:MOLN) Revenue Forecasts
Feb 10Molecular Partners (VTX:MOLN) Is In A Good Position To Deliver On Growth Plans
Jan 21How Much Of Molecular Partners AG (VTX:MOLN) Do Insiders Own?
Dec 17
Downgrade: Here's How Analysts See Molecular Partners AG (VTX:MOLN) Performing In The Near Term
Nov 21Shareholder Returns
| MOLN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | -3.4% | -10.4% | 1.0% |
| 1Y | -43.5% | 5.5% | -2.5% |
Return vs Industry: MOLN underperformed the Swiss Biotechs industry which returned 8.7% over the past year.
Return vs Market: MOLN underperformed the Swiss Market which returned -2.8% over the past year.
Price Volatility
| MOLN volatility | |
|---|---|
| MOLN Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.3% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: MOLN's share price has been volatile over the past 3 months.
Volatility Over Time: MOLN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 168 | Patrick Amstutz | www.molecularpartners.com |
Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors.
Molecular Partners AG Fundamentals Summary
| MOLN fundamental statistics | |
|---|---|
| Market cap | CHF107.15m |
| Earnings (TTM) | -CHF61.98m |
| Revenue (TTM) | CHF7.04m |
15.2x
P/S Ratio-1.7x
P/E RatioIs MOLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOLN income statement (TTM) | |
|---|---|
| Revenue | CHF7.04m |
| Cost of Revenue | CHF47.84m |
| Gross Profit | -CHF40.81m |
| Other Expenses | CHF21.18m |
| Earnings | -CHF61.98m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 26, 2024
| Earnings per share (EPS) | -1.89 |
| Gross Margin | -579.80% |
| Net Profit Margin | -880.70% |
| Debt/Equity Ratio | 0% |
How did MOLN perform over the long term?
See historical performance and comparison